Growth Hormone Secretagogues & GHRH Analogs
Tesamorelin
Last reviewed: 2026-11-19
Evidence status & limitations
Trials support a specific indication in adults with HIV-associated lipodystrophy; it is not approved for general weight management.
Regulatory status
FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.
Egrifta SV / Egrifta WR · HIV-associated Lipodystrophy
Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; not an indication for general weight management.
Authoritative label record
Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.
WADA prohibited status: current list and contextKnown risks & open questions
Elevated IGF-1, impaired glucose tolerance, edema and hypersensitivity are documented concerns.
Key sources
Indication-specific regulatory sources and editorial screen checked November 19, 2026. This is not an exhaustive systematic review; consult current labels.
Related compounds
- CJC-1295
Same target family · A 29-amino-acid chain. · Early human trials
- Examorelin
Same scientific class · A 6-amino-acid chain. · Early human trials
- Ipamorelin
Same scientific class · A 5-amino-acid chain. · Early human trials
- Modified GRF (1–29)
Same target family · A 29-amino-acid chain. · Cell/lab studies only
- Pralmorelin
Same scientific class · A 6-amino-acid chain. · Early human trials